Prevention and treatment of aluminum toxicity including chelation therapy: Status and research needs

Journal of Toxicology and Environmental Health - Part A

Volumn 48, Issue 6, 1996, Pages 667-683

  Yokel, Robert A ^a   Ackrill, Peter ^b   Burgess, Ellen ^c   Day, J Philip ^d   Domingo, Jose L ^e   Flaten, Trond Peder ^f   Savory, John ^g  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^g UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 4 PYRIDONE DERIVATIVE; ALUMINUM; CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; FLUORIDE; SILICATE;

ALZHEIMER DISEASE; CHELATION; COMPLEX FORMATION; CONFERENCE PAPER; DEGENERATIVE DISEASE; DIALYSIS; DRUG ACCUMULATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; TOXICITY;

ALUMINUM; ANIMALS; ANTIDOTES; CHELATION THERAPY; DEFEROXAMINE; HUMANS; POISONING; RESEARCH DESIGN;

ORYCTOLAGUS CUNICULUS;

EID: 0029796623     PISSN: 15287394     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Ackrill, P., Ralston, A. J., Day, J. P., and Hodge, K. C. 1980. Successful removal of aluminium from patient with dialysis encephalopathy. Lancet ii:692-693.
2. Ackrill, P., Day, J. P., Garstang, F. M., Hodge, K. C., Metcalfe, P. J., Benzo, Z., Hill, K., Ralston, A. J., Ball, J., and Denton, J. 1982. Treatment of fracturing renal osteodystrophy by desferrioxamine. Proc. Eur. Dial. Transplant. Assoc. 19:203-207.
3. Ackrill, P., Ralston, A. J., and Day, J. P. 1986. Role of desferrioxamine in the treatment of dialysis encephalopathy. Kidney Int. 29(suppl. 18):S-104-S-107.
4. Ahn, H.-W., Fulton, B., Moxon, D., and Jeffery, E. H. 1995. Interactive effects of fluoride and aluminum uptake and accumulation in bones of rabbits administered both agents in their drinking water. J. Toxicol. Environ. Health 44:337-350.
5. Allain, P., Chaleil, D., Mauras, Y., Beaudeau, G., Varin, M. C., Poignet, J. L., Ciancioni, C., Ang, K. S., Cam, G., and Simon, P. 1987. Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis. Clin. Chim. Acta 170:331-338.
6. Anthone, S., Ambrus, C. M., Kohli, R., Min, I., Anthone, R., Stadler, A., Stadler, I., and Vladutiu, A. 1995. Treatment of aluminum overload using a cartridge with immobilized desferrioxamine. J. Am. Soc. Nephrol. 6:1271-1277.
7. 1) on absorption of iron. Vet. Hum. Toxicol. 32:159-61.
8. Berdoukas, V., Bentley, P., Frost, H., and Schnebli, H. P. 1993. Toxicity of oral iron chelator L1. Lancet 341:1088.
9. Birchall, J. D., Bellia, J. L., and Roberts, N. B. 1996. On the mechanisms underlying the essentiality of silicon interactions with aluminium and copper. Coord. Chem. Rev., in press.
10. Boelaert, J. R., Fenves, A. Z., and Coburn, J. W. 1991. Deferoxamine therapy and mucormycosis in dialysis patients: Report of an international registry. Am. J. Kidney Dis. 18:660-667.
11. Boelaert, J. R., de Locht, M., Van Cutsem, J., Kerrels, V., Cantinieaux, B., Verdonck, A., Van Landuyt, H. W., and Schneider, Y.-J. 1993. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J. Clin. Invest. 91:1979-1986.
12. Burden, T. J., Powell, J. J., Thompson, R. P. H., and Taylor, P. D. 1995. Optimal accuracy, precision and sensitivity of inductively coupled plasma optical emission spectrometry: Bioanalysis of aluminium. J. Anal. Atomic Spectr. 10:259-266.
13. Candy, J. M., Klinowski, J., Perry, R. H., Perry, E. K., Fairbairn, A., Oakley, A. E., Carpenter, T. A., Atack, J. R., Blessed, G., and Edwardson, J. A. 1986. Aluminosilicates and senile plaque formation in Alzheimer's disease. Lancet i:354-357.
14. Carlisle, E. M., and Curran, M. J. 1987. Effect of dietary silicon and aluminum on silicon and aluminum levels in rat brain. Alzheimer Dis. Assoc. Disord. 1:83-89.
15. Cases, A., Kelly, J., Sabater, F., Torras, A., Grino, M. C., Lopez-Pedret, J., and Revert, L. 1990. Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine. Nephron 56:19-23.
16. Chazan, J. A., Lew, N. L., and Lowrie, E. G. 1991. Increased serum aluminum - An independent risk factor for mortality in patients undergoing long-term hemodialysis. Arch. Intern. Med. 151:319-322.
17. Connor, D. J., Harrell, L. E., and Jope, R. S. 1989. Reversal of an aluminum-induced behavioral deficit by administration of deferoxamine. Behav. Neurosci. 103:779-783.
18. Cory-Slechta, D. A., Weiss, B., and Cox, C. 1987. Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy. J. Pharmacol. Exp. Ther. 243:804-813.
19. Crapper McLachlan, D. R., Dalton, A. J., Kruck, T. P. A., Bell, M. Y., Smith, W. L., Kalow, W., and Andrews, D. F. 1991. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337:1304-1308.
20. Crapper McLachlan, D. R., Smith, W. L., and Kruck, T. P. 1993. Desferrioxamine and Alzheimer's disease: Video home behavior assessment of clinical course and measures of brain aluminum. Ther. Drug Monit. 15:602-607.
21. Dang, S., Rasmussen, C. A., and Levine, S. M. 1994. Immunocytochemical localization of desferrioxamine in the kidney, liver and brain of the developing and adult mouse: Implications for drug processing and therapeutic mechanisms. Res. Commun. Chem. Pathol. Pharmacol. 86:43-57.
22. Davenport, A., Davison, A. M., Newton, K. E., Will, E. J., Giles, G. R., and Toothill, C. 1990. Urinary aluminium excretion following renal transplantation and the effect of pulse steroid therapy. Ann. Clin. Biochem. 27:25-32.
23. Davies, P., Weiner, M. A., Holleman, D. R., and Goldstone, J. R. 1991. Desferrioxamine for Alzheimer's disease. Lancet 338:325.
24. Day, J. P., Hewitt, C. D., Ackrill, P., and Hill, K. 1989. Clearance of aluminium desferrioxamine by haemodialysis using a polysulfone high flux membrane. Contrib. Nephrol. 74:101-105.
25. D'Haese, P. C., Eamberts, L. V., Verpooten, G. A., Vaneerdeweg, W., Jurgens, A., Arakelian, S., Babloyan, A., Digenis, P., Tjalma, W., and DeBroe, M. E. 1994. Urinary and biliary excretion of aluminoxamine and ferrioxamine in dogs with various renal function. Kidney Int. 45:76-84.
26. Domingo, J. L., Llobet, J. M., Gómez, M., and Corbella, J. 1986. Acute aluminium intoxication: A study of the efficacy of several antidotal treatments in mice. Res. Commun. Chem. Pathol. Pharmacol. 53:93-104.
27. Domingo, J. L., Gómez, M., Llobet, J. M., and Corbella, J. 1988a. Comparative effects of several chelating agents on the toxicity, distribution and excretion of aluminum. Hum. Toxicol. 7:259-262.
28. Domingo, J. L., Gómez, M., Llobet, J. M., and Corbella, J. 1988b. Citric, malic and succinic acids as possible alternatives to deferoxamine in aluminum toxicity. J. Toxicol. Clin. Toxicol. 26:67-79.
29. Ellenberg, R., King, A. L., Sica, D. A., Posner, M., and Savory, J. 1990. Cerebrospinal fluid aluminum levels following deferoxamine. Am. J. Kidney Dis. 16:157-159.
30. Elorriaga, R., Fernández Martin, J. L., Menéndez Fraga, P., Naves, M. L., Braga, S., and Cannata, J. B. 1992. Aluminium removal: Short- and long-term preliminary results with L1 in rats. Drugs Today 28(A):177-182.
31. Evers, A., Hancock, R. D., Martell, A. E., and Motekaitis, R. J. 1989. Metal ion recognition in ligands with negatively charged oxygen donor groups. Complexation of Fe(III), Ga(III), In(III), Al(III), and other highly charged metal ions. Inorg. Chem. 28:2189-2195.
32. Fasman, G. D., Perczel, A., and Moore, C. D. 1995. Solubilization of β-amyloid-(1-42)-peptide: Reversing the β-sheet conformation induced by aluminum with silicates. Proc. Natl. Acad. Sci. USA 92:369-371.
33. Fernández-Martín, J. L., Menéndez-Fraga, P., Canteros, M. A., Díaz-López, J. B., and Cannata-Andía, J. B. 1994. Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1). Clin. Chim. Acta 230:137-145.
34. Flaten, T. P., Alfrey, A. C., Birchall, J. D., Savory, J., and Yokel, R. A. 1996. Status and future concerns of clinical and environmental aluminum toxicology. J. Toxicol. Environ. Health 48:527-541.
35. Freundlich, M., Zilleruelo, G., Abitbol, C., Strauss, J., Faugere, M.-C., and Malluche, H. H. 1985. Infant formula as a cause of aluminium toxicity in neonatal uraemia. Lancet ii:527-529.
36. Froment, D. H., Buddington, B., Miller, N. L., and Alfrey, A. C. 1989. Effect of solubility on the gastrointestinal absorption of aluminum from various aluminum compounds in the rat. J. Lab. Clin. Med. 114:237-242.
37. Garruto, R. M. 1991. Pacific paradigms of environmentally-induced neurological disorders: Clinical, epidemiological and molecular perspectives. Neurotoxicology 12:347-378.
38. Gómez, M., Domingo, J. L., del Castillo, D., Llobet, J. M., and Corbella, J. 1994a. Comparative aluminium mobilizing actions of several chelators in aluminium-loaded uraemic rats. Hum. Exp. Toxicol. 13:135-139.
39. Gómez, M., Llobet, J. M., Santafé, M., Domingo, J. L., and Corbella, J. 1994b. A short-term toxicity study of L1, a potential aluminum and iron chelator, in normal rats. In Metal ions in biology and medicine, vol. 3, eds. P. Collery, L. A. Poirier, N. A. Littlefield, and J. C. Etienne, pp. 85-89. Paris: John Libbey Eurotext.
40. Gómez, M., Domingo, J. L., del Castillo, D., Llobet, J. M., and Corbella, J. 1995. Four-week oral toxicity study of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in uremic rats. Hum. Exp. Toxicol. 373:346-348.
41. Good, P. F., Olanow, C. W., and Perl, D. P. 1992. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: A LAMMA study. Brain Res. 593:343-346.
42. Hamilton, K. O., Stallibrass, L., Hassan, I., Jin, Y., Halleux, C., and Mackay, M. 1994. The transport of two iron chelators, desferrioxamine B and L1, across Caco-2 monolayers. Br. J. Haematol. 86:851-857.
43. Harris, W. R., Berthon, G., Day, J. P., Exley, C., Flaten, T. P., Forbes, W. F., Kiss, T., Orvig, C., and Zatta, P. F. 1996. Speciation of aluminum in biological systems. J. Toxicol. Environ. Health 48:543-568.
44. Hewitt, C. D., Ackrill, P., and Day, J. P. 1986. Determination of aluminium in red blood cells. In Aluminium and other trace elements in renal disease, ed. A. Taylor, pp. 313-317. London: Baillière Tindall.
45. Hodge, K. C., Day, J. P., O'Hara, M., Ackrill, P., and Ralston, A. J. 1981. Critical concentrations of aluminium in water used for dialysis. Lancet ii:802-803.
46. Huang, Y., Savory, J., Herman, M. M., Nicholson, J. R., Reyes, J. C., Boyd, J. C., and Wills, M. R. 1995. Quantitative evaluation of Al maltolate-induced neurodegeneration with subsequent Al removal by desferrioxamine treatment. Neurotoxicology 16:291-296.
47. Klein, G. L. 1995. Aluminum in parenteral solutions revisited-Again. Am. J. Clin. Nutr. 61:449-456.
48. Kontoghiorghes, G. J. 1990. Chelators affecting iron absorption in mice. Arzneim. Forsch./Drug Res. 40:1332-1335.
49. Kontoghiorghes, G. J. 1995A. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review. Analyst 120:845-851.
50. Kontoghiorghes, G. J. 1995b. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. Toxicol. Lett. 80:1-18.
51. Kontoghiorghes, G. J., Agarwal, M. B., Tondury, P., Kersten, M. J., Jaeger, M., Vreugdenhil, G., Vania, A., and Rahman, Y. E. 1993. Future of oral iron chelator deferiprone (L1). Lancet 341:1479-1480.
52. Kontoghiorghes, G. J., Barr, J., and Baillod, R. A. 1994. Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Arzneim. Forsch./Drug Res. 44:522-526.
53. Kraus, A. S., and Forbes, W. F. 1992. Aluminum, fluoride and the prevention of Alzheimer's disease. Can. J. Public Health 83:97-100.
54. Kruck, T. P. A., Fisher, E. A., and McLachlan, D. R. C. 1993. A predictor for side effects in patients with Alzheimer's disease treated with deferoxamine mesylate. Clin. Pharmacol. Ther. 53:30-37.
55. Maitani, T., Kubota, H., Hori, N., Yoshihira, K., and Takeda, M. 1994. Distribution and urinary excretion of aluminium injected with several organic acids into mice: Relationship with chemical state in serum studied by the HPLC-ICP method. J. Appl. Toxicol. 14:257-261.
56. Martell, A. E., Motekaitis, R. J., and Smith, R. M. 1990. Aluminium complexes of hydroxyaliphatic and hydroxyaromatic ligands in aqueous systems - Some problems and solutions. Polyhedron 9:171-187.
57. McCarthy, J. T., Kurtz, S. B., and Mussman, G. V. 1987. Deferoxamine-enhanced fecal losses of aluminum and iron in a patient undergoing continuous ambulatory peritoneal dialysis. Am. J. Med. 82:367-370.
58. McLachlan, D. R. C. 1995. Aluminium and the risk for Alzheimer's disease. Environmetrics 6:233-275.
59. Mehta, J., Singhal, S., and Mehta, B. C. 1995. Deferiprone in iron overload. N. Engl. J. Med. 333:597-598.
60. Molitoris, B. A., Alfrey, P. S., Miller, N. L., Hasbargen, J. A., Kaehney, W. D., Alfrey, A. C., and Smith, B. J. 1987. Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation. Kidney Int. 31:986-991.
61. Murphy, E. J., Roberts, E., Anderson, D. K., and Horrocks, L. A. 1993. Cytotoxicity of aluminum silicates in primary neuronal cultures. Neuroscience 57:483-490.
62. O'Callaghan, J. P., and Miller, D. B. 1986. Diethyldithiocarbamate increased distribution of cadmium to brain but prevents cadmium-induced neurotoxicity. Brain Res. 370:354-358.
63. Partridge, N. A., Regnier, F. E., White, J. L., and Hem, S. L. 1989. Influence of dietary constituents on intestinal absorption of aluminum. Kidney Int. 35:1413-1417.
64. Pfannkuch, F., Bentley, P., and Schnebli, H. P. 1993. Future of oral iron chelator deferiprone (L1). Lancet 341:1480.
65. Poe, C. F., and Leberman, J. M. 1949. The effect of acid foods on aluminum cooking utensils. Food Technol. 3:71-74.
66. Porter, J. B., Hoyes, K. P., Abeysinghe, R. D., Brooks, P. N., Huehns, E. R., and Hider, R. C. 1991. Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice. Blood 78:2727-2734.
67. Savory, J., Exley, C., Forbes, W. F., Huang, Y., Joshi, J. G., Kruck, T., McLachlan, D. R. C., and Wakayama, I. 1996. Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered? J. Toxicol. Environ. Health 48:615-635.
68. Shore, D., and Wyatt, R. J. 1982. Research design issues: Antialuminum drug studies in Alzheimer's disease. Clin. Neuropharmacol. 5:337-343.
69. Silke, B., Fitzgerald, G. R., Hanson, S., Carmody, M., and O'Dwyer, W. F. 1978. Dialysis dementia and renal transplantation. Dial. Transplant. 7:486-487.
70. Singh, S., Epemolu, R. O., Ackerman, R., Mohammed, N. T., Damani, L. A., Porter, J. B., and Hider, R. C. 1992. Drug metabolism and its effects on the toxicity and efficacy of chelating agents. Presentation to Symposium on Aluminum Toxicity: Fact or Fiction?, Lo0uvain-la-Neuve, Belgium.
71. Slanina, P., Falkeborn, Y., Frech, W., and Cedergren, A. 1984. Aluminium concentrations in the brain and bone of rats fed citric acid, aluminium citrate or aluminium hydroxide. Food Chem. Toxicol. 22:391-397.
72. van Ginkel, M. F., van der Voet, G. B., D'Haese, P. C., De Broe, M., and de Wolff, F. A. 1993. Effect of citric acid and maltol on the accumulation of aluminum in rat brain and bone. J. Lab. Clin. Med. 121:453-460.
73. Verpooten, G. A., D'Haese, P. C., Boelaert, J. R., Becaus, I., Lamberts, L. V., and De Broe, M. E. 1992. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. Nephrol. Dial. Transplant. 7:931-938.
74. 239Pu deposit in rats. Health Phys. 27:152-153.
75. Wróbel, K., González, E. B., Wróbel, K., and Sanz-Medel, A. 1995. Aluminium and silicon speciation in human serum by ion-exchange high-performance liquid chromatography-electrothermal atomic absorption spectrometry and gel electrophoresis. Analyst 120:809-815.
76. Yokel, R. A. 1994. Aluminum chelation: Chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine. J. Toxicol. Environ. Health 41:131-174.
77. Yokel, R. A. 1996. Aluminum chelation by 3-hydroxypyridin-4-ones in the rat demonstrated by microdialysis. Biol. Trace Element Res. 53:193-203.
78. Yokel, R. A., and McNamara, P. J. 1988. Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. Toxicol. Appl. Pharmacol. 95:32-43.
79. Yokel, R. A., Lidums, V., and Ungerstedt, U. 1991. Aluminum mobilization by desferrioxamine assessed by microdialysis of the blood, liver and brain. Toxicology 66:313-324.
80. Yokel, R. A., Fredenburg, A. M., Meurer, K. A., and Skinner, T. L. 1995. Influence of lipophilicity on the bioavailability and disposition of orally active 3-hydroxypyridin-4-one metal chelators. Drug Metab. Dispos. 23:1178-1180.
81. Yokel, R. A., Meurer, K. A., Skinner, T. L., and Fredenburg, A. M. 1996. The 3-hydroxypyridin-4-ones more effectively chelate aluminum in a rabbit model of aluminum intoxication than does desferrioxamine. Drug Metab. Dispos. 24:105-111.
82. Zevin, S., Link, G., Grady, R. W., Hider, R. C., Peter, H. H., and Hershko, C. 1992. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: Studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores. Blood 79:248-253.